TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Antithrombotic therapy after TAVR: Comparing warfarin to DAPT, SAPT

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

EnCompass Technologies F2 embolic filter device TAVR embolic device

Interventional cardiologists perform world’s first TAVR with new embolic protection device

The device, designed with improved filtration and stability in mind, is now being investigated as part of a new pilot study. 

Thumbnail

TAVR controversy: Surgeon fired after saying cardiologist treated patients without proper credentials

An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet. 

Thumbnail

TAVR among 90-year-old patients: An updated look at mortality, hospital costs and more

In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 

The DurAVR transcatheter heart valve (THV), developed by Minnesota-based Anteris Technologies

New biomimetic TAVR valve, the first of its kind, linked to strong performance after 1 year

The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.

Abbott TriClip device for TEER

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TVT 2023: Cardiovascular Research Foundation announces late-breaking clinical trials

In addition to these 15 late-breaking clinical studies, TVT 2023 will feature live cases, hands-on training, poster presentations and much more.

Data on a next-generation balloon-expandable transcatheter heart valve

Next-gen TAVR valve, tested on patients for very first time, linked to high success rate

A new-look TAVR valve was tested on patients for the first time, leading researchers to say its use appears to be "feasible and safe." More research, of course, is still required. 

Displaying 177 - 184 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.